Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Certolizumab pegol Stories

2010-08-05 16:18:43

Biological agents may play an important role in maintaining remission in Crohn's disease, according to two new studies in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. "Post-surgical recurrence of Crohn's disease occurs very frequently. Unfortunately, none of the traditional drugs used to treat the naturally occurring disease has really shown a clear-cut benefit in this situation," said Dario R. Sorrentino, MD,...

2010-06-16 08:30:00

ATLANTA, June 16 /PRNewswire-FirstCall/ -- UCB today announced new Cimzia® (certolizumab pegol) data demonstrating rapid and sustained improvements in managing moderate to severe rheumatoid arthritis (RA) symptoms and pain for patients, as well as results of a survey showing the impact of RA pain on the daily lives of women, focusing on productivity and relationships, during the 2010 European League Against Rheumatism (EULAR) annual congress in Rome, Italy, June 16-19....

2010-05-02 08:15:00

ATLANTA, May 2 /PRNewswire/ -- UCB announced today results of an open-label extension study, PRECiSE 4 (P4), of Cimzia® (certolizumab pegol; CZP) demonstrating that Cimzia provides sustained efficacy over four years in moderate to severe Crohn's Disease patients regardless of whether patients were previously treated with infliximab (IFX) or infliximab-naive. Cimzia is indicated for reducing the signs and symptoms of Crohn's Disease and maintaining clinical response in...

2010-04-29 07:30:00

ATLANTA, April 29 /PRNewswire/ -- Studies and analyses of the Crohn's Disease (CD) treatment Cimzia® (certolizumab pegol) demonstrating new data will be exhibited at Digestive Disease Week (DDW) 2010, taking place in New Orleans from May 1-5, 2010. "Cimzia data at this year's DDW provide important and positive clinical insights, namely, that Cimzia offers long-term efficacy in multiple patient populations," said Cem Kayhan, MD, Associate Medical Director at UCB. "This...

2010-02-22 07:00:00

WALTHAM, Mass., Feb. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the premium price of Centocor Ortho Biotech/Janssen-Cilag's Stelara and Abbott's briakinumab will drive robust sales for both of these interleukin (IL)-12/IL-23 inhibitors in 2018 in the United States, France, Germany, Italy, Spain and the United Kingdom. The Pharmacor 2010 findings from...

2009-12-09 07:06:00

WALTHAM, Mass., Dec. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that compared to last year's analysis of U.S. patient-level claims data, TNF-alpha inhibitors are being used more often to treat newly diagnosed patients suffering from Crohn's disease. Three times as many newly diagnosed second-line patients received a TNF-alpha inhibitor versus one year ago (15.2 percent versus 5.6...

2009-11-02 07:00:00

WALTHAM, Mass., Nov. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the Crohn's disease drug market, the dominance of TNF-alpha inhibitors such as Abbott/Eisai's Humira and Centocor Ortho Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade will continue over the next decade. Sales of Humira and Remicade, which accounted for more than three-quarters of the market in 2008, will continue to...

2009-10-26 10:00:00

SAN DIEGO, Oct. 26 /PRNewswire/ -- According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study. These...

2009-10-26 10:00:00

SAN DIEGO, Oct. 26 /PRNewswire/ -- New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years. In a separate analysis, CIMZIA significantly improved...

2009-10-17 16:00:00

PHILADELPHIA, Oct. 17 /PRNewswire/ -- UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia® (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks. Cimzia® is approved for the treatment of adult...